Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
2017 · The Lancet Oncology · 1,113 citations
https://doi.org/10.1016/s1470-2045(17)30777-5
L
L. Mauriac
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
270
Papers
20.1K
Citations
54
h-index
114
i10-index
L. Mauriac is an academic researcher. The author has contributed to research in topics: Breast Cancer Treatment Studies & Cancer Treatment and Pharmacology & Estrogen and related hormone effects. The author has an h-index of 54, co-authored 230 publications.
Papers by this author
worksLetrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
2001 · Journal of Clinical Oncology · 1,062 citations
https://doi.org/10.1200/jco.2001.19.18.3808
Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group
2010 · European Journal of Cancer · 962 citations
https://doi.org/10.1016/j.ejca.2010.02.015
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
2003 · PubMed · 202 citations
Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi
1996 · British Journal of Cancer · 193 citations
https://doi.org/10.1038/bjc.1996.565
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
2011 · The Lancet Oncology · 125 citations
https://doi.org/10.1016/s1470-2045(11)70094-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat